ArticleChembiochem : a European journal of chemical biology2026
Sanger's Reagent-Mediated Prodrug for Light-Controlled Release of Camptothecin With Fluorescent Indication.
Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Stimuli-responsive prodrug system has emerged as an attractive approach to address the issues encountered by conventional chemotherapeutics. Among the growing arsenal of stimuli-responsive prodrug strategies, the photocaging approach occupies a privileged position because it replaces poorly controlled biological triggers with an external light stimulation, thereby offering a promising solution to the therapeutic limitations in cancer treatment. In this work, we have developed a Sanger's reagent based prodrug, Sanger-Naph-CPT, which enables light-controlled camptothecin (CPT) release in cancer cells via 400 nm light. Integrating a naphthalimide fluorescent reporter, the system allows real-time monitoring of drug release kinetics. The photocaged prodrug was characterized by HPLC/HRMS, confirming photodegradation under light. Confocal microscopy showed minimal baseline fluorescence in HeLa cells without irradiation, with robust fluorescence emerging postirradiation (intensity increasing with exposure time). MTT assays showed that, after light irradiation, Sanger-Naph-CPT exhibited dose-dependent cytotoxicity comparable to free CPT, demonstrating restored activity of released CPT. This dual-function platform combines light-triggered therapeutic activity and fluorescence reporting, offering a modular design for photocontrolled prodrugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.